Literature DB >> 25505289

A single amino acid change in inhibitory killer cell Ig-like receptor results in constitutive receptor self-association and phosphorylation.

Santosh Kumar1, Pabak Sarkar2, Malcolm J W Sim3, Sumati Rajagopalan1, Steven S Vogel2, Eric O Long4.   

Abstract

Signaling by immunoreceptors is often initiated by phosphorylation of cytosolic tyrosines, which then recruit effector molecules. In the case of MHC class I-specific inhibitory receptors, phosphorylation of cytosolic tyrosine residues within ITIMs results in recruitment of a protein tyrosine phosphatase that blocks activation signals. Recent work showed that signaling by an HLA-C-specific killer cell Ig-like receptor (KIR) is independent of signaling by activation receptors. It is not known how ITIM phosphorylation is initiated and regulated. In this article, we show that substitution of His-36 in the first Ig domain of KIR2DL1 with alanine (KIR2DL1-H36A) resulted in constitutive KIR2DL1 self-association and phosphorylation, as well as recruitment of tyrosine phosphatase SHP-1. Furthermore, substitution of His-36 with a similar bulky amino acid, phenylalanine, maintained the receptor in its unphosphorylated state, suggesting that steric hindrance by the His-36 side chain prevents constitutive KIR2DL1 self-association and ITIM phosphorylation. The equally strong phosphorylation of KIR2DL1 and KIR2DL1-H36A after inhibition of tyrosine phosphatase by pervanadate suggested that KIR2DL1-H36A is selectively protected from dephosphorylation. We propose that KIR phosphorylation is controlled by the accessibility of ITIM to tyrosine phosphatases and that KIR binding to HLA-C must override the hindrance that His-36 puts on KIR2DL1 self-association. Expression of KIR2DL1-H36A on NK cells led to stronger inhibition of lysis of HLA-C(+) target cells than did expression of wild-type KIR2DL1. These results revealed that ITIM phosphorylation is controlled by self-association of KIR and that His-36 serves as a gatekeeper to prevent unregulated signaling through KIR2DL1.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25505289      PMCID: PMC4282981          DOI: 10.4049/jimmunol.1401830

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  37 in total

1.  An improved bimolecular fluorescence complementation assay with a high signal-to-noise ratio.

Authors:  Yutaka Kodama; Chang-Deng Hu
Journal:  Biotechniques       Date:  2010-11       Impact factor: 1.993

2.  Using circular dichroism spectra to estimate protein secondary structure.

Authors:  Norma J Greenfield
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

3.  Energy migration alters the fluorescence lifetime of Cerulean: implications for fluorescence lifetime imaging Forster resonance energy transfer measurements.

Authors:  Srinagesh V Koushik; Steven S Vogel
Journal:  J Biomed Opt       Date:  2008 May-Jun       Impact factor: 3.170

4.  Plasmonics in Biology and Plasmon-Controlled Fluorescence.

Authors:  Joseph R Lakowicz
Journal:  Plasmonics       Date:  2006-03-01       Impact factor: 2.404

Review 5.  FcR-mediated inhibition of cell activation and other forms of coinhibition.

Authors:  C C Anderson; N R Sinclair
Journal:  Crit Rev Immunol       Date:  1998       Impact factor: 2.214

6.  Adhesion to target cells is disrupted by the killer cell inhibitory receptor.

Authors:  D N Burshtyn; J Shin; C Stebbins; E O Long
Journal:  Curr Biol       Date:  2000-06-29       Impact factor: 10.834

7.  The Ig-related killer cell inhibitory receptor binds zinc and requires zinc for recognition of HLA-C on target cells.

Authors:  S Rajagopalan; C C Winter; N Wagtmann; E O Long
Journal:  J Immunol       Date:  1995-11-01       Impact factor: 5.422

Review 8.  Visualization of molecular interactions using bimolecular fluorescence complementation analysis: characteristics of protein fragment complementation.

Authors:  Tom K Kerppola
Journal:  Chem Soc Rev       Date:  2009-09-04       Impact factor: 54.564

9.  Inhibitory receptor signaling via tyrosine phosphorylation of the adaptor Crk.

Authors:  Mary E Peterson; Eric O Long
Journal:  Immunity       Date:  2008-10-02       Impact factor: 31.745

Review 10.  The kinetic-segregation model: TCR triggering and beyond.

Authors:  Simon J Davis; P Anton van der Merwe
Journal:  Nat Immunol       Date:  2006-08       Impact factor: 25.606

View more
  5 in total

1.  Zinc-Induced Polymerization of Killer-Cell Ig-like Receptor into Filaments Promotes Its Inhibitory Function at Cytotoxic Immunological Synapses.

Authors:  Santosh Kumar; Sumati Rajagopalan; Pabak Sarkar; David W Dorward; Mary E Peterson; Hsien-Shun Liao; Christelle Guillermier; Matthew L Steinhauser; Steven S Vogel; Eric O Long
Journal:  Mol Cell       Date:  2016-04-07       Impact factor: 17.970

Review 2.  Natural killer cell cytotoxicity and its regulation by inhibitory receptors.

Authors:  Santosh Kumar
Journal:  Immunology       Date:  2018-04-11       Impact factor: 7.397

3.  Canonical and Cross-reactive Binding of NK Cell Inhibitory Receptors to HLA-C Allotypes Is Dictated by Peptides Bound to HLA-C.

Authors:  Malcolm J W Sim; Stacy A Malaker; Ayesha Khan; Janet M Stowell; Jeffrey Shabanowitz; Mary E Peterson; Sumati Rajagopalan; Donald F Hunt; Daniel M Altmann; Eric O Long; Rosemary J Boyton
Journal:  Front Immunol       Date:  2017-03-14       Impact factor: 7.561

4.  A Dual-Functional Orphan Response Regulator Negatively Controls the Differential Transcription of Duplicate groELs and Plays a Global Regulatory Role in Myxococcus.

Authors:  Li Zhuo; Tian-Yu Wan; Zhuo Pan; Jia-Ning Wang; Duo-Hong Sheng; Yue-Zhong Li
Journal:  mSystems       Date:  2022-03-30       Impact factor: 6.496

5.  The Size of Activating and Inhibitory Killer Ig-like Receptor Nanoclusters Is Controlled by the Transmembrane Sequence and Affects Signaling.

Authors:  Anna Oszmiana; David J Williamson; Shaun-Paul Cordoba; David J Morgan; Philippa R Kennedy; Kevin Stacey; Daniel M Davis
Journal:  Cell Rep       Date:  2016-05-19       Impact factor: 9.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.